Your browser doesn't support javascript.
loading
Application of a deuterium replacement strategy to modulate the pharmacokinetics of 7-(3,5-dimethyl-1H-1,2,4-triazol-1-yl)-3-(4-methoxy-2-methylphenyl)-2,6-dimethylpyrazolo[5,1-b]oxazole, a novel CRF1 antagonist.
Stringer, Rowan A; Williams, Gareth; Picard, Franck; Sohal, Bindi; Kretz, Olivier; McKenna, Jeff; Krauser, Joel A.
  • Stringer RA; Novartis Institutes for Biomedical Research, Horsham, West Sussex, UK (R.A.S., G.W., B.S., J.M.); and Novartis Pharma AG, Novartis Institutes for Biomedical Research, Drug Metabolism and Pharmacokinetics, Basel, Switzerland (F.P., O.K., J.A.K.).
Drug Metab Dispos ; 42(5): 954-62, 2014 May.
Article en En | MEDLINE | ID: mdl-24616265

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Oxazoles / Pirazoles / Receptores de Hormona Liberadora de Corticotropina / Deuterio Tipo de estudio: Prognostic_studies Límite: Animals / Humans / Male Idioma: En Año: 2014 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Oxazoles / Pirazoles / Receptores de Hormona Liberadora de Corticotropina / Deuterio Tipo de estudio: Prognostic_studies Límite: Animals / Humans / Male Idioma: En Año: 2014 Tipo del documento: Article